MX2020004475A - Composiciones y metodos antivirales de amplio espectro. - Google Patents

Composiciones y metodos antivirales de amplio espectro.

Info

Publication number
MX2020004475A
MX2020004475A MX2020004475A MX2020004475A MX2020004475A MX 2020004475 A MX2020004475 A MX 2020004475A MX 2020004475 A MX2020004475 A MX 2020004475A MX 2020004475 A MX2020004475 A MX 2020004475A MX 2020004475 A MX2020004475 A MX 2020004475A
Authority
MX
Mexico
Prior art keywords
methods
broad spectrum
spectrum antiviral
antiviral compositions
virus
Prior art date
Application number
MX2020004475A
Other languages
English (en)
Inventor
Frank Kayser
Stacy Remiszewski
Qun Sun
Lillian W Chiang
Eain Anthony Murphy
Sarah Jocelyn Fink
Original Assignee
Evrys Bio Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evrys Bio Llc filed Critical Evrys Bio Llc
Publication of MX2020004475A publication Critical patent/MX2020004475A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se presentan nuevos compuestos que contienen tiazol e isoquinolina que son útiles para tratar y/o prevenir infecciones virales de amplio espectro. También se presentan métodos para tratar y/o prevenir infecciones virales de amplio espectro. Estos compuestos han mostrado inhibición de la replicación de HCMV, virus de la influenza, virus Zika, virus BK y RSV en ensayos a base de células.
MX2020004475A 2017-10-18 2018-10-17 Composiciones y metodos antivirales de amplio espectro. MX2020004475A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762574067P 2017-10-18 2017-10-18
PCT/US2018/056379 WO2019079519A1 (en) 2017-10-18 2018-10-17 BROAD SPECTRUM ANTIVIRAL COMPOSITIONS AND METHODS

Publications (1)

Publication Number Publication Date
MX2020004475A true MX2020004475A (es) 2020-10-28

Family

ID=66173872

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020004475A MX2020004475A (es) 2017-10-18 2018-10-17 Composiciones y metodos antivirales de amplio espectro.
MX2022016281A MX2022016281A (es) 2017-10-18 2020-07-13 Composiciones y metodos antivirales de amplio espectro.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022016281A MX2022016281A (es) 2017-10-18 2020-07-13 Composiciones y metodos antivirales de amplio espectro.

Country Status (11)

Country Link
US (2) US11459321B2 (es)
EP (1) EP3697783A4 (es)
JP (2) JP7342010B2 (es)
KR (1) KR20200060772A (es)
CN (1) CN111819175A (es)
AU (2) AU2018350999B2 (es)
BR (1) BR112020007879A2 (es)
CA (1) CA3079396A1 (es)
IL (1) IL273990B1 (es)
MX (2) MX2020004475A (es)
WO (1) WO2019079519A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3479294A4 (en) 2016-07-01 2020-03-18 The Board of Regents of The University of Texas System METHODS, APPARATUSES AND SYSTEMS FOR CREATING THREE-DIMENSIONAL REPRESENTATIONS WITH GEOMETRIC AND SURFACE FEATURES OF BRAIN INJURY
EP4271675A1 (en) * 2020-12-31 2023-11-08 Evrys Bio, LLC Anti-tumor compositions and methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US6042820A (en) 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
US6472375B1 (en) 1998-04-16 2002-10-29 John Wayne Cancer Institute DNA vaccine and methods for its use
JP2010513519A (ja) 2006-12-22 2010-04-30 ミレニアム・ファーマシューティカルズ・インコーポレイテッド キナーゼインヒビター活性を有するある種のピラゾリン誘導体
US20150335657A1 (en) * 2014-05-05 2015-11-26 The Trustees Of Princeton University Methods for Modulating Sirtuin Enzymes
EP3757105B1 (en) * 2014-08-22 2024-07-24 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase inhibitory activity
CN107438435B (zh) * 2014-11-10 2020-12-04 埃弗里斯生物有限责任公司 抗-hcmv组合物和方法
WO2016077240A2 (en) 2014-11-10 2016-05-19 Forge Life Science, Llc Anti-hcmv compositions and methods
EP3240537B1 (en) * 2014-12-30 2020-09-09 F. Hoffmann-La Roche AG Novel tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis b virus infection
CN107624113B (zh) * 2015-05-04 2020-10-23 豪夫迈·罗氏有限公司 作为HBsAg (HBV 表面抗原)和HBV DNA 生成的抑制剂用于治疗乙型肝炎病毒感染的四氢吡啶并嘧啶和四氢吡啶并吡啶类化合物

Also Published As

Publication number Publication date
EP3697783A1 (en) 2020-08-26
AU2022256094B2 (en) 2023-07-20
IL273990A (en) 2020-05-31
JP7342010B2 (ja) 2023-09-11
KR20200060772A (ko) 2020-06-01
AU2018350999A1 (en) 2020-05-07
RU2020114888A3 (es) 2021-11-18
CA3079396A1 (en) 2019-04-25
JP2023162363A (ja) 2023-11-08
WO2019079519A1 (en) 2019-04-25
JP2021500401A (ja) 2021-01-07
BR112020007879A2 (pt) 2020-10-13
AU2018350999B2 (en) 2022-09-08
MX2022016281A (es) 2023-02-09
US20210139475A1 (en) 2021-05-13
IL273990B1 (en) 2024-07-01
CN111819175A (zh) 2020-10-23
EP3697783A4 (en) 2023-04-26
US11459321B2 (en) 2022-10-04
US20230416241A1 (en) 2023-12-28
RU2020114888A (ru) 2021-11-18
AU2022256094A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
CL2017001798A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas.
CL2020000937A1 (es) Anticuerpo multiespecífico.
MX2018005292A (es) Inhibidores de acc y usos de los mismos.
BR112018071678A2 (pt) compostos terapêuticos úteis para o tratamento profilático ou terapêutico de uma infecção por vírus hiv
CL2016000493A1 (es) Inhibidores de polimerasa hcv.
PH12018501962A1 (en) Stablizied soluble pre-fusion rsv f proteins
CL2018002874A1 (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso (divisional de solicitud n° 2413-2016).
EA201691726A1 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
MX2018009633A (es) Inhibidor de indoleamina-2,3-dioxigenasa (ido).
CL2015003615A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
CU24435B1 (es) Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il
EA201992232A1 (ru) Композиции и способы для иммуноонкологии
MX2022000453A (es) Compuestos útiles para tratar infecciones por virus de influenza.
CO2018006947A2 (es) Novedoso bacteriófago pas-mup-1 de pasteurella multocida y su uso para inhibir la proliferación de pasteurella multocida
BR112018014794A2 (pt) pirimidinas substituídas com arila para uso em infecção pelo vírus influenza
BR112017017142A2 (pt) métodos e composições para redução de produtos de amplificação não específicos
BR112018073238A2 (pt) vírus oncolíticos compreendendo esrage e métodos de tratamento de câncer
UY36204A (es) Derivados de insoindolina.
EA201891586A1 (ru) Антипролиферативные соединения и их фармацевтические композиции и применения
EA201891576A1 (ru) Функционализированные пентановые кислоты для применения при инфекциях, вызванных вирусом гриппа
MX2020004475A (es) Composiciones y metodos antivirales de amplio espectro.
CL2017000151A1 (es) Derivados de piridona
CL2021002807A1 (es) Anticuerpos y métodos para el tratamiento de la infección por influenza a
CL2021002307A1 (es) Uso de virus oncolíticos para el tratamiento del cáncer
CL2019003063A1 (es) Heteroaril fenil aminoquinolinas y sus análogos.